Pancreatic Cancer Research

ResearcherLund UniversityActive in the last 2 years

Dingyuan Hu

Matched on ORCID iD 0000-0002-7149-5501; OpenAlex author ID A5101598796. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2018: 2 papers · 2019: 7 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. CLCA1 Modulates Pancreatic Cancer Proliferation via SIRT1-HIF-1α Pathway. Co-author DOI 10.7754/clin.lab.2025.250721↗
  2. YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. Co-author DOI 10.1186/s12967-020-02254-7↗
  3. Proteomic and genomic profiling of pancreatic cancer. Co-author DOI 10.1007/s10565-019-09465-9↗
  4. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. Co-author DOI 10.1016/j.ebiom.2019.04.008↗
  5. Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. Co-author DOI 10.1016/j.trsl.2019.06.003↗
  6. Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/00365521.2018.1561937↗
  7. Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer. Co-author DOI 10.1080/00365521.2019.1574360↗
  8. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-019-1574-z↗
  9. The Hippo Signaling Pathway in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13474↗
  10. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-018-5013-2↗
  11. Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.23929↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qimin Zhou · 10 shared papers, 2018–2020 · strength 1.01
  2. Roland E. Andersson · 10 shared papers, 2018–2020 · strength 1.01
  3. Daniel Ansari · 10 shared papers, 2018–2020 · strength 1.01
  4. Monika Posaric Bauden · 6 shared papers, 2018–2020 · strength 0.55
  5. György Marko‐Varga · 4 shared papers, 2018–2020 · strength 0.35
  6. Limiao Lin · 1 shared paper, 2026 · strength 0.33
  7. Mengtao Zhou · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.